Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investors on edge

Abbott Laboratories started 2026 with slightly better-than-expected Q1 figures, a completed mega-deal for Exact Sciences and ongoing infant formula litigation. What this mix of growth, dividends and legal pressure could mean for the stock.

Abbott Laboratories opened 2026 with a complex mix of tailwinds and headwinds: the healthcare group modestly beat Wall Street expectations in the first quarter, closed its roughly US$21 billion acquisition of cancer diagnostics specialist Exact Sciences and continues to navigate extensive infant formula and securities litigation, according to an analysis published in May 2026 by Simply Wall St based on company disclosures and market data as of early 2026 (Simply Wall St as of 05/2026).

Recent coverage of Abbott on MarketBeat highlighted that the company reported Q1 2026 earnings per share of US$1.15 on revenue of US$11.16 billion, slightly ahead of consensus estimates and up 7.8% year over year, while analysts maintained a "Moderate Buy" average rating and the board confirmed a quarterly dividend of US$0.63 per share, implying an annualized yield of about 3% at the time of publication (MarketBeat as of 05/14/2026).

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare; medical devices, diagnostics, nutrition, established pharmaceuticals
• Headquarters/country: Abbott Park, Illinois, United States
• Core markets: North America, Europe, Asia-Pacific and emerging markets
• Key revenue drivers: Medical devices, diagnostics, nutrition products and branded generics
• Home exchange/listing venue: New York Stock Exchange (ticker: ABT)
• Trading currency: US dollar (USD)

Abbott Laboratories: core business model

Abbott Laboratories is a diversified healthcare company whose business model spans four major pillars: diagnostic tests, medical devices, nutritional products and established pharmaceutical brands. This diversification is designed to reduce dependence on any single product line or therapeutic area and to provide multiple avenues for growth across different stages of the healthcare value chain, especially in the US and other major markets.

In diagnostics, Abbott focuses on laboratory systems, point-of-care testing and rapid diagnostics that hospitals and clinics use to identify diseases and monitor chronic conditions. The diagnostics portfolio ranges from core lab analyzers for high-volume testing to rapid tests used in physicians’ offices or retail settings, positioning the company as a key player when health systems invest in automation and efficiency. This business became particularly visible during the pandemic and continues to play a role as testing demand normalizes.

Medical devices are another key pillar, including cardiovascular devices such as stents and structural heart products, diabetes care solutions like continuous glucose monitoring systems, and neuromodulation devices for pain and movement disorders. These devices generate recurring revenue through consumables, service and replacement cycles, and they tend to be closely linked to demographic trends such as aging populations and the rising prevalence of chronic diseases in the United States and globally.

The nutrition segment covers infant formulas, adult nutrition drinks and specialized clinical nutrition products. While this business provides relatively steady demand and strong branding opportunities, it has also exposed Abbott to regulatory and legal scrutiny following infant formula recalls in past years, which still influence investor perception according to recent commentary summarizing ongoing litigation and regulatory discussions (Simply Wall St as of 05/2026).

Finally, Abbott’s established pharmaceuticals division concentrates on branded generics, particularly in emerging markets where demand for affordable, trusted medicines is expanding with rising incomes and improving healthcare access. This business tends to face pricing pressure but offers scale benefits and diversification away from the often more volatile US reimbursement environment, helping to balance the group’s overall earnings profile.

Main revenue and product drivers for Abbott Laboratories

Recent financial data show that Abbott’s revenue growth in early 2026 was driven largely by medical devices and diagnostics, with total Q1 2026 revenue of US$11.16 billion increasing 7.8% year over year and slightly topping analyst expectations of about US$10.99 billion, as reported in a mid-May 2026 MarketBeat update on the stock’s performance and earnings details (MarketBeat as of 05/14/2026).

One of the most closely watched product families is Abbott’s diabetes care franchise, which includes continuous glucose monitoring systems for people with diabetes. These products operate on a razor-and-blades model where sensors need to be replaced regularly, creating recurring revenue streams and reinforcing customer loyalty. As payers in the US and other countries increasingly recognize the value of digital health tools for chronic disease management, such systems can support both volume growth and incremental innovation.

Cardiovascular and structural heart devices also play an important role, benefiting from procedural growth as populations age and as minimally invasive techniques become more widely adopted. Devices for transcatheter interventions, heart failure management and remote monitoring can improve patient outcomes and reduce hospital stays, supporting demand from providers and payers. Abbott competes in these markets with other large medtech players, and product cycles are driven by clinical trial data, regulatory approvals and physician adoption curves.

In diagnostics, the company’s core lab systems and point-of-care platforms generate revenue through initial instrument placements, reagents and maintenance contracts. Hospital consolidation and efforts to centralize laboratory operations often favor large, integrated diagnostics providers, and Abbott aims to leverage this trend with comprehensive system offerings. While pandemic-related testing surges have normalized, routine testing volumes continue to recover, and new menu additions can drive incremental growth.

The nutrition segment remains a significant contributor, particularly with adult nutrition brands aimed at aging populations and clinical settings. However, infant formula continues to attract regulatory attention, and Abbott has been managing the operational and reputational impact of past recall events and related lawsuits, as highlighted in recent legal risk summaries that emphasize the scope of infant formula and securities litigation the company faces (Simply Wall St as of 05/2026).

On the capital allocation side, Abbott’s regular dividend is an important component of total return for many shareholders. MarketBeat noted that the company declared a quarterly dividend of US$0.63 per share to be paid in mid-May 2026 to shareholders of record in mid-April, corresponding to an annualized payout of US$2.52 per share and a yield of around 3% at the time the article was published (MarketBeat as of 05/14/2026). This dividend policy, combined with the company’s long history of consecutive increases, is often seen as a signal of confidence in cash flow resilience.

Exact Sciences acquisition: expanding into cancer diagnostics

A central strategic development for Abbott in 2026 is the completion of its roughly US$21 billion acquisition of Exact Sciences, a company known for its colorectal cancer screening tests and broader cancer diagnostics portfolio. Simply Wall St reported in May 2026 that Abbott closed the transaction in recent months, framing it as a major expansion into cancer diagnostics at a time when investors are reassessing the company’s growth profile (Simply Wall St as of 05/2026).

The deal gives Abbott a broader footprint in non-invasive cancer screening, an area expected to see increasing demand as healthcare systems emphasize early detection and population-level screening programs. Exact Sciences’ tests for colorectal and other cancers can complement Abbott’s existing diagnostics platforms by offering higher-value assays that sit on top of installed testing infrastructure, potentially enhancing the economics of its diagnostics segment if integration is managed effectively.

From a financial perspective, a transaction of around US$21 billion is significant even for a large-cap company like Abbott, and the integration process could influence margins, capital structure and future investment flexibility. Simply Wall St noted that while Q1 2026 results modestly exceeded expectations, the complexity of integrating a major acquisition, combined with valuation questions and ongoing legal issues, could shape how quickly any potential benefits from cancer diagnostics are reflected in market sentiment (Simply Wall St as of 05/2026).

Strategically, the acquisition aligns with a broader industry trend in which large healthcare companies seek to build integrated platforms around diagnostics, data and therapeutics. For Abbott, adding Exact Sciences’ oncology-focused capabilities could deepen its relationships with healthcare providers and payers, particularly in the US, where cancer screening guidelines and reimbursement decisions heavily influence test adoption. Execution risk remains, but the transaction underscores management’s commitment to diagnostics as a long-term growth engine.

Earnings quality, guidance and balance sheet considerations

MarketBeat’s coverage of Abbott’s April 2026 earnings release highlighted that the company reported Q1 2026 earnings per share of US$1.15, surpassing the consensus estimate of US$1.14 by one cent, and that net margin reached about 13.9% with return on equity around 17.6% for the quarter, illustrating solid profitability metrics for a diversified healthcare player (MarketBeat as of 05/14/2026).

In terms of forward-looking statements, the same report stated that Abbott set its full-year 2026 guidance at US$5.38 to US$5.58 in earnings per share and provided guidance for Q2 2026 in the range of US$1.25 to US$1.31 per share. Analysts tracked by MarketBeat were forecasting about US$5.48 in earnings per share for the current year at the time, which positions the midpoint of management’s guidance close to the Street’s expectations and suggests a relatively narrow band of potential outcomes under current assumptions (MarketBeat as of 05/14/2026).

Balance sheet strength is an important consideration as the company digests the Exact Sciences acquisition and continues to invest in research, development and capital projects. MarketBeat noted that Abbott reported a current ratio of around 1.39, a quick ratio of about 1.01 and a debt-to-equity ratio of roughly 0.56, indicating a moderate level of leverage and adequate liquidity in the context of its size and cash generation capacity (MarketBeat as of 05/14/2026).

Valuation metrics provide another lens on the stock. According to Investing.com’s data snapshot for Abbott updated in 2026, the company has been trading at a price-to-earnings ratio around the high teens and a price-to-book multiple in the mid-single digits, placing it within the typical range for large, profitable medical device and diagnostics companies but with some premium reflecting its diversified business model (Investing.com as of 2026). Simply Wall St’s narrative estimated that Abbott could generate about US$59.7 billion in revenue and US$9.5 billion in earnings by 2029, implying approximate annual revenue growth of nearly 10% and a substantial earnings increase over several years, though such forecasts are inherently uncertain (Simply Wall St as of 05/2026).

StockAnalysis data show that Abbott’s market capitalization stood at about US$178 billion at the end of March 2026 and that the company had experienced a double-digit percentage decline in market value over the preceding year, reflecting the combined impact of sector rotation, litigation headlines and shifting expectations for growth and interest rates (StockAnalysis as of 03/30/2026). For long-term shareholders, the interaction between earnings growth, dividends and potential multiple expansion or contraction remains a central driver of total return.

Legal and regulatory overhang: infant formula and securities litigation

Beyond pure financial metrics, Abbott’s risk profile is shaped by ongoing legal and regulatory challenges, particularly in its nutrition business. Simply Wall St’s May 2026 overview noted that the company continues to face extensive infant formula-related litigation and a securities class action linked to past product and disclosure issues, underscoring that legal and regulatory pressure is an important counterweight to the positive narrative around dividends and diagnostics expansion (Simply Wall St as of 05/2026).

Such litigation can lead to direct financial costs in the form of settlements or penalties, higher operating expenses related to compliance and quality improvements, and potential constraints on product distribution if regulators impose conditions. For a consumer-facing segment like infant nutrition, reputational effects can also influence market share and pricing power, especially in the US where parents and healthcare professionals closely follow safety communications and recall announcements from regulators and manufacturers.

Regulatory scrutiny may extend beyond individual incidents to broader oversight of manufacturing practices, supply chain resilience and transparency in communication with healthcare providers and consumers. This can require sustained investments in plant upgrades, testing protocols and internal monitoring systems. While these initiatives can ultimately strengthen product quality and trust, they may weigh on margins in the near term and add to the complexity of managing a global nutrition franchise.

Investors tracking Abbott’s risk profile therefore pay attention not only to headline litigation developments but also to qualitative signals from management commentary about quality systems, remediation efforts and engagement with authorities. The balance between resolving past issues and maintaining innovation and marketing focus in nutrition will likely influence how this segment contributes to overall growth and profitability over the next few years.

Why Abbott Laboratories matters for US investors

For US investors, Abbott is a prominent name in the healthcare sector, combining characteristics of a medical device company, a diagnostics provider and a consumer health business. Its primary listing on the New York Stock Exchange and inclusion in major US equity indices make it a significant component of many diversified portfolios, pension funds and healthcare-focused exchange-traded funds that allocate capital to large, stable franchises.

Abbott’s exposure to key US healthcare trends—such as aging demographics, the rising prevalence of diabetes and cardiovascular disease, and the shift towards value-based care—means that its results can serve as a barometer for broader sector dynamics. When the company reports earnings, investors often look for signals on elective procedure volumes, hospital capital spending and payer behavior that may have implications for other medtech and diagnostics firms operating in the same environment.

At the same time, the stock can be sensitive to US policy developments, including reimbursement decisions by public and private insurers, regulatory updates from the Food and Drug Administration and debates around drug and device pricing. Changes in interest rates and macroeconomic conditions in the United States also influence valuation, particularly for dividend-paying, large-cap healthcare companies that are sometimes treated as defensive holdings during periods of market volatility.

Conclusion

Abbott Laboratories enters the middle of 2026 as a diversified healthcare company balancing solid operating performance, an ambitious expansion into cancer diagnostics and a meaningful legal and regulatory overhang in its nutrition business. Recent Q1 2026 results modestly exceeded expectations, management’s guidance aligns broadly with analyst forecasts and the company continues to underline its commitment to shareholder returns with a roughly 3% dividend yield and a long history of quarterly payouts, according to MarketBeat’s latest coverage (MarketBeat as of 05/14/2026).

At the same time, the completion of the roughly US$21 billion Exact Sciences acquisition adds integration and valuation questions, while extended infant formula and securities litigation underscores that governance, quality control and regulatory relationships are central to the investment case, as highlighted in Simply Wall St’s May 2026 analysis (Simply Wall St as of 05/2026). For US investors, Abbott offers exposure to multiple healthcare growth drivers and a long-standing dividend stream, but its future share price path will likely depend on how effectively management integrates new assets, sustains innovation in devices and diagnostics and resolves legal and regulatory challenges without undermining financial flexibility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.